Zenas BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	110.64	319.74	56.86	67.21
Short-Term Investments	232.55	31.02	-	-
Cash & Short-Term Investments	343.19	350.77	56.86	67.21
Cash Growth	-2.16%	516.93%	-15.40%	-
Other Current Assets	7.98	5.16	2.95	1.24
Total Current Assets	351.17	355.92	59.8	68.44
Net Property, Plant & Equipment	1.39	1.19	1.01	1.8
Long-Term Investments	17.27	-	-	-
Other Long-Term Assets	13.81	12.86	7.36	4.33
Total Assets	383.64	369.97	68.18	74.58
Accounts Payable	7.11	17.14	5.4	5.82
Accrued Expenses	54.42	39.37	17.31	19.44
Current Portion of Leases	1.12	0.79	0.56	0.72
Total Current Liabilities	62.65	57.29	23.26	25.97
Long-Term Leases	0.21	0.22	0.26	0.81
Other Long-Term Liabilities	78.64	-	20.3	-
Total Long-Term Liabilities	78.85	0.22	20.56	0.81
Total Liabilities	141.5	57.51	43.82	26.78
Common Stock	0.01	0	-	-
Additional Paid-in Capital	1,007	699.65	4.65	1.03
Accumulated Other Comprehensive Income	-0.06	0.19	0.04	-0.04
Retained Earnings	-765.13	-387.39	-230.4	-193.28
Total Common Shareholders' Equity	242.14	312.46	-225.72	-192.29
Minority Interest	-	-	250.09	240.09
Shareholders' Equity	242.14	312.46	24.37	47.8
Total Liabilities & Equity	383.64	369.97	68.18	74.58
Total Debt	1.33	1	0.81	1.53
Net Cash (Debt)	341.87	349.76	56.04	65.68
Net Cash Growth	-2.26%	524.09%	-14.67%	-
Net Cash Per Share	7.64	26.50	36.60	0.04
Book Value	242.14	312.46	-225.72	-192.29
Book Value Per Share	5.41	23.67	-147.42	-0.13
Tangible Book Value	242.14	312.46	-225.72	-192.29
Tangible Book Value Per Share	5.41	23.67	-147.42	-0.13

Updated Mar 16, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q